Loading...
menu
Search
AI Chat
AI Strategies
Products
Markets
News
Resources
Pricing
Home
ETF
ONC
ONC
-
Add to Watchlist
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
Overview
Technical
News
ONC News
BeOne Medicines to Report Q4 and Full Year 2025 Financial Results
4d ago
Newsfilter
Amazon and BeOne Medicines Show Promising Prospects
Feb 02 2026
NASDAQ.COM
February Investment Opportunities: Amazon and Three Stocks to Buy
Feb 02 2026
Fool
FDA Accepts Summit Therapeutics' BLA for Ivonescimab
Jan 29 2026
Benzinga
S&P 500 and Dow Reverse Gains as Nasdaq Narrows Upturn
Jan 08 2026
Yahoo Finance
S&P 500 and Dow Retreat from Highs, Eli Lilly and Google Flash Buy Signals
Jan 08 2026
Yahoo Finance
Jazz Pharmaceuticals Reports Ziihera Trial Shows Significant Survival Benefits
Jan 07 2026
Benzinga
BeOne Reports ZIIHERA Trial Results, Significant Survival Improvement Observed
Jan 06 2026
Businesswire
BeOne Medicines (ONC) Shares Oversold with RSI at 28.4, Potential Buy Signal
Dec 30 2025
NASDAQ.COM
BeOne Medicines to Present at 2026 J.P. Morgan Healthcare Conference
Dec 23 2025
Yahoo Finance
BeOne Medicines Receives FDA Fast Track Designation for BGB-B2033 in Liver Cancer Treatment
Dec 18 2025
Newsfilter
Kymera Stock Soars as Secretive Hedge Fund Acquires $172 Million Stake.
Dec 14 2025
Barron's
BeOne Showcases BRUKINSA's Leadership in CLL Treatment at ASH 2025
Dec 08 2025
Newsfilter
BeOne Medicines Presents 52.4% Efficacy of Sonrotoclax at ASH Meeting
Dec 07 2025
Businesswire
BeOne's Sonrotoclax Shows Significant Efficacy in MCL and CLL Treatments
Dec 07 2025
Newsfilter
BeOne Medicines Reports Rapid MRD Negativity in Treatment-Naive CLL with Sonrotoclax and BRUKINSA, Even in High-Risk Patients
Dec 07 2025
Benzinga
Show More News
